ClinicalTrials.gg

Program

trastuzumab rezetecan

Also written as “SHR-A1811”, “SHR-A1811 for Injection” and “SHR-A1811 Injection”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Colorectal Neoplasms · Ovarian Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Jun 15, 202236 company-led studies, 32 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine3632 open or runningphase 3since Jun 15, 2022Jun 18, 2020Dec 2026phase 2 · NCT06840002

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since Jun 18, 2020.

  1. Sep 9, 2024Phase 2 study in Untreated Early-stage or Locally Advanced Breast CancerNCT06592625 · 60 planned · China
  2. Nov 25, 2024Phase 1 study in Advanced Breast CancerNCT06710990 · 17 enrolled · China
  3. Feb 10, 2025Phase 3 study in Ovarian NeoplasmsNCT06828354 · 300 planned · China
  4. Feb 17, 20252 phase 2 studiesNCT06840002, NCT06859775
  5. Jun 26, 2025Phase 2 study in RecurrenceNCT07051486 · 60 planned · China
  6. Jul 31, 2025Phase 2 study in Stomach NeoplasmsNCT07110571 · 200 planned · China
  7. Aug 1, 20252 phase 3 studiesNCT07111832, NCT07118527
  8. Aug 17, 2025Phase 2 study in Solid TumorNCT07140393 · 120 planned · China
  9. Sep 22, 2025Phase 3 study in Early-stage or Locally Advanced HER2-positive Breast CancerNCT07196774 · 740 enrolled · China
  10. Nov 27, 2025Phase 1 study in Solid TumorNCT07275242 · 107 planned · China
  11. Mar 19, 2026Phase 2 study in Unresectable Locally Recurrent Breast CancerNCT07497386 · 150 planned · China
  12. Jun 23, 20262 phase 3 studiesNCT07676162, NCT07679360
  13. Aug 28, 2026Phase 2 study in Advanced Colorectal Cancer Expressing HER2NCT07796763 · 48 planned · United States
  14. Oct 19, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07896005 · 436 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Ovarian NeoplasmsNCT06840002
  2. Dec 2026Primary completion: phase 2 study in Advanced Non-small Cell Lung CancerNCT05482568
  3. Dec 31, 2026Primary completion: phase 2 study in HER2 Expression / Amplification in Patients With Biliary Tract CancerNCT06413745
  4. Dec 31, 2026Primary completion: phase 3 study in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneNCT05424835

TargetBeta

ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 36 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07896005Carcinoma, Non-Small-Cell Lung · China3Not yet recruitingFeb 2031436
NCT07796763Advanced Colorectal Cancer Expressing HER2 · United States2Not yet recruitingMay 1, 202848
NCT07679360Triple Negative Breast Neoplasms · China3RecruitingDec 20301,000
NCT07676162Advanced Colorectal Cancer · China3RecruitingSep 2029300
NCT07497386Unresectable Locally Recurrent Breast Cancer · China2RecruitingJun 2028150
NCT07275242Solid Tumor · China1RecruitingJun 2027107
NCT07196774Early-stage or Locally Advanced HER2-positive Breast Cancer · China3Active, not recruitingDec 2027740
NCT07140393Solid Tumor · China2RecruitingOct 2027120
NCT07118527Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma · China3RecruitingOct 2030600
NCT07111832Triple Negative Breast Neoplasms · China3RecruitingMar 2028400
NCT07110571Stomach Neoplasms · China2RecruitingAug 2026200
NCT07051486Recurrence · China2RecruitingFeb 202660
NCT06859775Recurrence · China2RecruitingOct 2026100
NCT06840002Ovarian Neoplasms · China2RecruitingDec 2026150
NCT06828354Ovarian Neoplasms · China3RecruitingMay 2027300
NCT06710990Advanced Breast Cancer · China1CompletedOct 15, 202517
NCT06592625Untreated Early-stage or Locally Advanced Breast Cancer · China2Not yet recruitingFeb 28, 202660
NCT06430437Non-Small Cell Lung Cancer With HER2- Mutations · China3RecruitingFeb 2026300
NCT06413745HER2 Expression / Amplification in Patients With Biliary Tract Cancer · China2Active, not recruitingDec 31, 202659
NCT06199973Advanced Colorectal Cancer · China3Active, not recruitingApr 2026130
NCT06222879Breast Neoplasms · China2RecruitingOct 31, 2026350
NCT06126640HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy · China3Active, not recruitingApr 20301,615
NCT06123494HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · China3RecruitingJun 30, 2027360
NCT06057610Breast Neoplasms · China3Active, not recruitingJul 15, 2026868
NCT05896020Gynaecological Malignancies · China2RecruitingJun 15, 2026225
NCT05845138Breast Neoplasms · China2RecruitingDec 31, 2024116
NCT05814354Breast Neoplasms · China3Active, not recruitingMar 20, 2026551
NCT05792410Breast Neoplasms2Not yet recruitingFeb 27, 2024300
NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma · China2RecruitingDec 2027258
NCT05482568Advanced Non-small Cell Lung Cancer · China2RecruitingDec 2026324
NCT05424835HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane · China3Active, not recruitingDec 31, 2026381
NCT05349409Advanced Solid Tumors · China2By invitationNov 30, 2024212
NCT05353361Breast Neoplasms · China2UNKNOWNDec 31, 2025402
NCT04818333Advanced Non-small Cell Lung Cancer · China2Active, not recruitingJun 2025157
NCT04513223Stomach Neoplasms · China1CompletedMar 28, 2025101
NCT04446260Advanced Solid Tumors · United States, Australia, China and more1CompletedJun 4, 2025396

How it is read

Names in the registry

  • “SHR-A1811”, 17 entries
  • “SHR-A1811 for Injection”, 4 entries
  • “SHR-A1811 Injection”, 3 entries
  • “Trastuzumab Rezetecan for Injection”, 2 entries
  • “SHR-A1811 and capecitabine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.